Differentiating mild cognitive impairment due to a depressive episode from early neurodegeneration is challenging among older people. Although neuropsychological tests are routine diagnostic assessments in the evaluation of cognitive decline, in contrast to dementia syndromes, they are often perceived as non-specific in the differentiation of affective and neurodegenerative mild cognitive impairment. Furthermore, depression may represent not only a risk factor for developing dementia but also a prodromal symptom of incipient neurodegeneration. In a university memory disorder clinic setting, we investigated 90 middle-aged and older individuals (57.8% women) suffering from mild cognitive impairment, presenting with or without current or previous depressive disorder. Using discriminance analysis and a multivariate analysis of variance, we show that impairments in executive functioning and attention were predictive towards cognitive impairment developed during a depressive episode. Reduced verbal fluency was also predictive towards depression-associated cognitive impairment, whereas memory was relatively preserved in these patients. Our data suggest that in addition to biological markers, specific neuropsychological profiles can be helpful to separate different etiologies of mild cognitive impairment.
Introduction
The assessment of cognitive decline in older people is challenging due to an accumulating number of possible dyscognitive factors that need to be considered throughout the lifespan. Within the diagnostic evaluation of cognitive impairment, the symptom spectrum ranges from physiological age-associated changes in cognition to progressive neurodegenerative disease. Besides different dementia syndromes, a history of late-life depression is frequently associated with persisting cognitive deficits affecting multiple cognitive domains [1] [2] [3] . Memory performance, attention, and executive functions as well as information processing speed can be impaired in acute and remitted depression [1] [2] [3] [4] . Furthermore, depression-associated cognitive impairment seems to be modulated by frontal lobe dysfunction and changes in subcortical emotion processing regions including the amygdala, ventral striatum, and periaqueductal gray [2, 5] . We recently demonstrated extrahippocampal cortical thinning among patients with clinically relevant cognitive deficits and a depressive episode [6] , whereas patients with prodromal dementia exhibit structural changes in adjacent medial temporal lobe regions [7] . There is a complex and yet poorly understood relationship between late-life depression and neurodegeneration. About one-third of patients with mild cognitive impairment (MCI) suffer from coincident depression [8] . Depression may represent an independent risk factor for dementia development as well as a prodromal symptom of dementia [9] . Furthermore, 50% of elderly patients with remitted major depression meet the diagnostic criteria for MCI and approximately one-fourth can be classified as amnestic type (aMCI) [4] . Later-age onset of first episode depression seems to be a risk factor for consecutive aMCI development [4] . The shorter duration of an untreated depressive episode is associated with reduced depression-related disability [10] . In cognitive impairment preceding Alzheimer's dementia, the aMCI subtype shows higher dementia conversion rates when compared with non-amnestic MCI types [11] , suggesting preclinical neurodegeneration. However, it adds to the clinical and possible neuropathological syndrome overlap, like that in latelife depression; specific depressive symptoms like anhedonia, dysphoria, and apathy as well as subclinical mood changes are associated with Alzheimer's disease-associated characteristics: high amyloid burden and hippocampal atrophy [12, 13] . Depressed aMCI patients show even higher dementia conversion rates, suggesting a prodromal character of specific affective symptoms in dementia development [14] .
Although it is challenging for a clinician, the differentiation of affective and neurodegenerative cognitive impairment is important for establishing diagnostic re-evaluation strategies and individual therapy. The variability of cognitive deficits associated with mood changes [5] , as well as the amnestic impairment in major depression, complicates the diagnostic classification of older-age MCI [4] . Although neuropsychological testing should complement diagnostic biomarkers obtained with brain imaging and cerebrospinal fluid analysis, it is often perceived as non-specific in the differentiation of the affective and neurodegenerative MCI etiology among older people. However, recent data suggest differences in neuropsychological performance among aMCI patients with no history of depression compared with individuals experiencing persisting cognitive deficits after remitted late-life depression [15] . Given the sensitivity and specificity limitations of established biomarkers for neurodegenerative diseases (e.g., the levels of specific beta-amyloid and protein tau species in cerebrospinal fluid, or changes in glucose metabolism and beta-amyloid deposition detected with positron emission tomography), it seems to be important to acknowledge the diagnostic potential of detailed neuropsychological testing. Physicians should recognize the diagnostic value of these valid and non-invasive tools.
Using detailed neuropsychological examinations and discriminance analysis, our aim was to identify neurocognitive characteristics in older patients with MCI that contribute to the differentiation of an affective or neurodegenerative etiology.
Methods

Participants and Procedures
Ninety patients (52 women and 38 men) suffering from mild cognitive impairment (Petersen criteria [11] ) participated in this cross-sectional study. We recruited these individuals through our memory clinic (university hospital, outpatient service) from January 2016 to December 2017. We included all patients who presented with memory impairment for the first time and who were subsequently diagnosed with MCI. We excluded patients with specific correlates for the cognitive impairment other than present or previous depression, such as relevant cerebrovascular disease, brain tumor, or sedating medications. We also did not include patients with school education less than 8 years or non-native German speakers. After providing complete description of the study to the patients, we obtained written informed consent according to our university's ethics committee regulations. This study was approved by the institutional review board of the Technische Universität Dresden (EK 491112015).
Study participants underwent diagnostic assessments including detailed medical and neurocognitive evaluation, laboratory testing, and brain imaging. In addition to patients with aMCI and non-amnestic MCI (both groups without past or current depression), we classified patients with cognitive impairment developed during a depressive episode (ICD-10 criteria) as depressive MCI (dMCI) ( Table 1 ).
Statistical Analyses
Consistent with our prior data on the diagnostic value of clinical parameter compositions [16] , we utilized a discriminance analysis [17] to investigate whether individual performance across different neurocognitive domains would differentiate between the diagnostic groups "depressive MCI (dMCI)", "amnestic MCI (aMCI)," and "other" (MCI; neither depressive nor amnestic). We further performed a multivariate analysis of variance (MANOVA) to control for age-specific effects on group discrimination for each parameter included in the discriminance analysis. Statistical computations were conducted within the R (3.44) statistical programming environment [18] . For the discriminance analysis, we used the "ade4" package [19, 20] , accounting for missing values with "missMDA" [21] .
Results
Among our study population, 38 patients were diagnosed with dMCI (5 participants with current depression, 13 with remitted previous depression, and 20 with current depression and previous depressive episodes). Twenty-two participants were diagnosed with aMCI (no history of depression) and 30 with other (neither amnestic nor depressive) MCI. Further demographic characteristics are illustrated in Table 1 .
The discriminance analysis resulted in a significant randomization test (p = .004). Two specific compositions of diagnostic parameters ("components") can be described to separate the three patient groups (Fig. 1) . Separation accuracy was acc = 65%. Using a MANOVA to investigate the component that significantly contributed to group separation (component 1: F(26,150) = 2.25, p = .001), we confirmed the possibility to discriminate between dMCI and aMCI (p < .01), but not between other groups (Fig. 1 ). Component 2 did not reach significance. Impairment in amnestic tasks (CERAD word list recall (− .49, p < .001) and CERAD word list reminders (− .21, p = .037)) was predictive towards aMCI. Executive functioning and attention deficits (Wechsler memory scale-revised digit span (.341, p = .001); trail making test part A (.433, p < .001); trail making test part B (.461, p < .001)), as well as reduced verbal fluency (.376, p < .001), were predictive towards dMCI (Fig. 2) . The factor age did not contribute to group separation (F(13,74) = 1.45, p = .15). Fig. 1 Group separation. The graphs illustrate that patients with cognitive impairment developed during a depressive episode (dMCI) can be discriminated from individuals with amnestic mild cognitive impairment (aMCI) using specific compositions of neurocognitive tests ("components") in a discriminance analysis. Shown are factor score densities resulting from the significant component (component 1). Dashed lines represent group centroids 
Discussion
This study demonstrates distinct neurocognitive profiles in dMCI and aMCI contributing to diagnostic group separation. Neuropsychological performance within memory, executive functions, attention, and language domains contributed to this finding. Whereas memory was relatively preserved in dMCI, these patients show a prominent dysexecutive and attention deficit accompanied by impairment in verbal fluency. The MCI concept refers to cognitive changes between physiological aging and dementia. MCI patients perform below age norms in neuropsychological tests, but they are not demented. Irrespective of having no obvious impairment in daily functioning, MCI patients are a heterogeneous group with respect to neurocognitive profiles, the syndrome's clinical course, and dementia progression rates [22] . Although the number of impaired cognitive domains contributes to clinical course prediction [22] , the relationship between MCI and depression remains poorly understood. From a clinical perspective, it can be challenging to differentiate between MCI due to depression and/or neurodegeneration in elderly subjects [23, 24] . When investigating multiple cognitive domains, Zihl and colleagues [24] did not demonstrate significant differences in cognitive performance between MCI patients with and without depression, although cognitive deficits within a depressive episode can persist after remission [4] . In contrast, others revealed differences in neuropsychological profiles in aMCI compared with patients with remitted late-life depression [15] . This variability may reflect insufficient diagnostic criteria or even a common pathway disorder [24] . Therefore, any improvement in determining the affective or neurodegenerative MCI etiology would be beneficial for the individual patient, given the important differences in disease progression, prognosis, and therapy. Our data illustrate that detailed but clinically applicable neurocognitive examination contributes to differentiate cognitive dysfunction attributable to depression or neurodegeneration. Recognizing the variance of neurocognitive performance, our relatively small sample size indicates a statistically robust finding. However, long-term investigations are necessary to confirm the individual trajectories of cognitive and affective symptoms.
In addition to investigating cerebrospinal fluid and brain imaging markers [12, 13] , our results suggest that appreciating neurocognitive profiles rather than single test results complements diagnostic assessments beyond the simple confirmation of deficits across cognitive domains. Clinicians should be aware of this potential and recommend appropriate neurocognitive investigations in older patients presenting with MCI. They should educate their patients with respect to the specific value of detailed neuropsychological testing; Fig. 2 Discriminating neurocognitive parameters. The colored bars represent neurocognitive parameters that significantly contributed to group separation within component 1 of the discriminance analysis (blue: predictive towards aMCI, red: predictive towards dMCI). Light gray bars represent parameters without significant contribution to the group separation however, a neuropsychological examination must be correlated with other clinical observations. Then these test results may contribute to aligning a patient's impression with distinct pathological cognitive performance. For example, identifying an attention deficit being responsible for subjective memory impairment could have diagnostic and even therapeutic implications for an individual. Detailed neuropsychological testing can also be helpful to detect diagnostic inconsistencies, such as severe deficits in various tests despite preserved reported everyday functioning. There exist multiple neuropsychological test batteries for people varying in age or in the severity of overall cognitive functioning. The specific composition of tests should always include comprehensive tests for different cognitive domains, e.g., memory (verbal and visual), attention, processing speed, executive functioning, and language, as well as basic measures of intelligence. Patients with MCI should undergo the same testing procedures every 12 months, with possibly shorter or longer intervals depending on regular clinical evaluations, aimed at detecting any progression to dementia as early as possible.
The main limitations of this study are the relatively small sample size and the cross-sectional design. It would be interesting to investigate how specific neuropsychological profiles in patients with MCI are associated with future trajectories of cognitive decline. Other study limitations include the utilization of data obtained from patients' reports (e.g., the number of previous depressive episodes) or subjective measures of disease burden or disease-associated impairment, which may not always correspond with the extent of specific neuropathology across individual people.
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